June 25, 2014
1 min read
Save

Iluvien receives marketing authorization in Italy for chronic DME treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Alimera Sciences announced it has received marketing authorization from the Italian Medicines Agency for Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema, according to a company press release.

Iluvien has now been granted marketing authorizations in all seven EU countries in which we initially applied,” Dan Myers, Alimera’s president and CEO, said in the press release. “Additionally, we are engaged in a Repeat Use Procedure through Mutual Recognition to obtain a positive opinion for approval from another 10 EU countries.”

Iluvien is a designated C class product in Italy, meaning that is currently available only to private-paying patients. If Iluvien reaches H class designation, patient access to Iluvien will be expanded, the release said.